Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study

S. Maschi, A. Clavenna, R. Campi, B. Schiavetti, M. Bernat, M. Bonati

Research output: Contribution to journalArticle

Abstract

Objective: To determine the incidence of early adverse effects associated with antidepressant drug use during pregnancy. Design: Prospective, controlled cohort study. Setting: A Drug and Health Information Centre in Milan, Italy. Population: A total of 200 neonates exposed to antidepressants in utero and 1200 controls. Methods: Women who took antidepressants during pregnancy and delivered liveborn children between 1995 and 2003 were selected. Each case was matched for maternal age and gravidity to six randomly selected controls (not exposed to teratogenic drugs or drugs known to cause neonatal side effects). Odds ratio was estimated for attributable risks. Main outcome measures: Neonatal adverse events and Special Care Unit admission rate, assessed through an interview with the mothers. Results: Of the 200 neonates exposed to antidepressants in utero, 14 had adverse events and 3 required Special Care Unit admission. Jaundice (n = 5), agitation (n = 3) and respiratory distress (n = 2) were the most common symptoms. In the control group, 50 newboms had side effects and no statistically significant differences in the prevalence rate compared to the exposed group were found, even after stratification for drugs and pregnancy period of exposure. Only the prematurity rate was significantly higher in exposed compared to non-exposed newborns (OR = 2.31; 95% CI 1.14-4.63). Conclusions: These results do not support an association between antidepressant exposure and unsafe fetal and neonatal outcomes in newborns. However, a collaborative international multicentre epidemiological monitoring of the use of psychotropic drugs during pregnancy is needed in order to guarantee pregnant women and their children safe and effective treatments, both at brief and long time from exposure.

Original languageEnglish
Pages (from-to)283-289
Number of pages7
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume115
Issue number2
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Pregnancy Outcome
Antidepressive Agents
Cohort Studies
Newborn Infant
Pregnancy
Pharmaceutical Preparations
Epidemiological Monitoring
Gravidity
Information Centers
Psychotropic Drugs
Maternal Age
Anniversaries and Special Events
Jaundice
Italy
Pregnant Women
Odds Ratio
Mothers
Outcome Assessment (Health Care)
Interviews
Control Groups

Keywords

  • Antidepressive agents
  • Infant
  • Neonatal abstinence syndrome
  • Newborn
  • Pregnancy outcome

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Neonatal outcome following pregnancy exposure to antidepressants : A prospective controlled cohort study. / Maschi, S.; Clavenna, A.; Campi, R.; Schiavetti, B.; Bernat, M.; Bonati, M.

In: BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 115, No. 2, 01.2008, p. 283-289.

Research output: Contribution to journalArticle

@article{3801552aba5541c99dfa0858725cabaf,
title = "Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study",
abstract = "Objective: To determine the incidence of early adverse effects associated with antidepressant drug use during pregnancy. Design: Prospective, controlled cohort study. Setting: A Drug and Health Information Centre in Milan, Italy. Population: A total of 200 neonates exposed to antidepressants in utero and 1200 controls. Methods: Women who took antidepressants during pregnancy and delivered liveborn children between 1995 and 2003 were selected. Each case was matched for maternal age and gravidity to six randomly selected controls (not exposed to teratogenic drugs or drugs known to cause neonatal side effects). Odds ratio was estimated for attributable risks. Main outcome measures: Neonatal adverse events and Special Care Unit admission rate, assessed through an interview with the mothers. Results: Of the 200 neonates exposed to antidepressants in utero, 14 had adverse events and 3 required Special Care Unit admission. Jaundice (n = 5), agitation (n = 3) and respiratory distress (n = 2) were the most common symptoms. In the control group, 50 newboms had side effects and no statistically significant differences in the prevalence rate compared to the exposed group were found, even after stratification for drugs and pregnancy period of exposure. Only the prematurity rate was significantly higher in exposed compared to non-exposed newborns (OR = 2.31; 95{\%} CI 1.14-4.63). Conclusions: These results do not support an association between antidepressant exposure and unsafe fetal and neonatal outcomes in newborns. However, a collaborative international multicentre epidemiological monitoring of the use of psychotropic drugs during pregnancy is needed in order to guarantee pregnant women and their children safe and effective treatments, both at brief and long time from exposure.",
keywords = "Antidepressive agents, Infant, Neonatal abstinence syndrome, Newborn, Pregnancy outcome",
author = "S. Maschi and A. Clavenna and R. Campi and B. Schiavetti and M. Bernat and M. Bonati",
year = "2008",
month = "1",
doi = "10.1111/j.1471-0528.2007.01518.x",
language = "English",
volume = "115",
pages = "283--289",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Neonatal outcome following pregnancy exposure to antidepressants

T2 - A prospective controlled cohort study

AU - Maschi, S.

AU - Clavenna, A.

AU - Campi, R.

AU - Schiavetti, B.

AU - Bernat, M.

AU - Bonati, M.

PY - 2008/1

Y1 - 2008/1

N2 - Objective: To determine the incidence of early adverse effects associated with antidepressant drug use during pregnancy. Design: Prospective, controlled cohort study. Setting: A Drug and Health Information Centre in Milan, Italy. Population: A total of 200 neonates exposed to antidepressants in utero and 1200 controls. Methods: Women who took antidepressants during pregnancy and delivered liveborn children between 1995 and 2003 were selected. Each case was matched for maternal age and gravidity to six randomly selected controls (not exposed to teratogenic drugs or drugs known to cause neonatal side effects). Odds ratio was estimated for attributable risks. Main outcome measures: Neonatal adverse events and Special Care Unit admission rate, assessed through an interview with the mothers. Results: Of the 200 neonates exposed to antidepressants in utero, 14 had adverse events and 3 required Special Care Unit admission. Jaundice (n = 5), agitation (n = 3) and respiratory distress (n = 2) were the most common symptoms. In the control group, 50 newboms had side effects and no statistically significant differences in the prevalence rate compared to the exposed group were found, even after stratification for drugs and pregnancy period of exposure. Only the prematurity rate was significantly higher in exposed compared to non-exposed newborns (OR = 2.31; 95% CI 1.14-4.63). Conclusions: These results do not support an association between antidepressant exposure and unsafe fetal and neonatal outcomes in newborns. However, a collaborative international multicentre epidemiological monitoring of the use of psychotropic drugs during pregnancy is needed in order to guarantee pregnant women and their children safe and effective treatments, both at brief and long time from exposure.

AB - Objective: To determine the incidence of early adverse effects associated with antidepressant drug use during pregnancy. Design: Prospective, controlled cohort study. Setting: A Drug and Health Information Centre in Milan, Italy. Population: A total of 200 neonates exposed to antidepressants in utero and 1200 controls. Methods: Women who took antidepressants during pregnancy and delivered liveborn children between 1995 and 2003 were selected. Each case was matched for maternal age and gravidity to six randomly selected controls (not exposed to teratogenic drugs or drugs known to cause neonatal side effects). Odds ratio was estimated for attributable risks. Main outcome measures: Neonatal adverse events and Special Care Unit admission rate, assessed through an interview with the mothers. Results: Of the 200 neonates exposed to antidepressants in utero, 14 had adverse events and 3 required Special Care Unit admission. Jaundice (n = 5), agitation (n = 3) and respiratory distress (n = 2) were the most common symptoms. In the control group, 50 newboms had side effects and no statistically significant differences in the prevalence rate compared to the exposed group were found, even after stratification for drugs and pregnancy period of exposure. Only the prematurity rate was significantly higher in exposed compared to non-exposed newborns (OR = 2.31; 95% CI 1.14-4.63). Conclusions: These results do not support an association between antidepressant exposure and unsafe fetal and neonatal outcomes in newborns. However, a collaborative international multicentre epidemiological monitoring of the use of psychotropic drugs during pregnancy is needed in order to guarantee pregnant women and their children safe and effective treatments, both at brief and long time from exposure.

KW - Antidepressive agents

KW - Infant

KW - Neonatal abstinence syndrome

KW - Newborn

KW - Pregnancy outcome

UR - http://www.scopus.com/inward/record.url?scp=36849031341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849031341&partnerID=8YFLogxK

U2 - 10.1111/j.1471-0528.2007.01518.x

DO - 10.1111/j.1471-0528.2007.01518.x

M3 - Article

C2 - 17903222

AN - SCOPUS:36849031341

VL - 115

SP - 283

EP - 289

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 2

ER -